Correlation of Bcl-2 and p53 Expression in Primary Breast Tumors and Corresponding Metastatic Lymph Nodes

Cancer

Volumn 98, Issue 12, 2003, Pages 2554-2559

  Arun, Banu ^a,b   Kilic, Gokhan ^a   Yen, Charles ^a   Foster, Barbara ^a   Yardley, Denise ^a   Gaynor, Richard ^a   Ashfaq, Raheela ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bcl 2; Breast carcinoma; Lymph nodes; p53; Prognostic marker

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADULT; ANALYTICAL EQUIPMENT; APOPTOSIS; ARTICLE; AXILLARY LYMPH NODE; BREAST TUMOR; CELL CYCLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

APOPTOSIS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0345098484     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11853     Document Type: Article

References (38)

1. Kuerbitz S, Plunkett B, Walsh W, Kastan M. Wild-type p53 is a cell checkpoint determinant following irradiation. Proc Natl Acad Sci U S A. 1992;89:7491-7495.
2. Kardinal CG, Veith R. Prevention of breast cancer in high-risk women. J La State Med Soc. 1999;151:198-201.
3. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways [see comments]. Nature. 1993;362:849-852.
4. El-Deiry WS, Harper JW, O'Conner PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994;54:1169-1174.
5. Miyashita T, Harigai M, Hanada M, Reed JC, Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54:3131-3135.
6. Allred DC, Elledge R, Clark GM, Fuqua SA. The p53 tumor suppressor gene in human breast cancer. In: Dickson RB, Lippman ME, editors. Mammary tumorigenesis and malignant progression. New York: Kluwer Academic, 1994:63-77.
7. Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science. 1984;226:1097-1099.
8. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440-442.
9. Bhargava V, Kell DL, van de Rijn M, Warnke RA. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol. 1994;145:535-540.
10. Hellemans P, VanDam PA, Weyler J, van Oosterom AT, Buytaert P, VanMarck E. Prognostic value of bcl-2 expression in invasive breast cancer. Br J Cancer. 1995;72:354-360.
11. Kobayashi S, Iwase H, Ito Y, et al. Clinical significance of bcl-2 gene expression in human breast cancer tissues. Breast Cancer Res Treat. 1997;42:173-181.
12. Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 1998;82:1296-1302.
13. Reed JC. Balancing cell life and death: bax, apoptosis, and breast cancer. J Clin Invest. 1996;97:2403-2404.
14. Rosfjord EC, Dickson RB. Growth factors, apoptosis, and survival of mammary epithelial cells. J Mammary Gland Biol Neoplasia. 1999;4:229-237.
15. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
16. Ryan JJ, Prochownik E, Gottlieb CA, et al. c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci U S A. 1994;91:5878-5882.
17. Le MG, Mathieu MC, Douc-Rasy S, et al. c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients. Int J Cancer. 1999;84:562-567.
18. Callahan R. p53 mutations, another breast cancer prognostic factor. J Natl Cancer Inst. 1992;84:826-827.
19. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst. 1993;85:200-206.
20. Elledge RM, Allred DC. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat. 1998;52:79-98.
21. Silvestrini R, Benini E, Daidone MG, et al. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1993;85:965-970.
22. Thor AD, Moore DH II, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 1992;84:845-855.
23. Gasparini G, Toi M, Verderio P, et al. Prognostic significance of p53, angiogenesis, and other conventional features in operable breast cancer: subanalysis in node-positive and node-negative patients. Int J Oncol. 1998;12:1117-1125.
24. Silvestrini R, Daidone MG, Benini E, et al. Validation of p53 accumulation as a predictor of distant metastasis at 10 years of follow-up in 1400 node-negative breast cancers. Clin Cancer Res. 1996;2:2007-2013.
25. Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol. 2000;39:327-333.
26. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med. 1995;1:1029-1034.
27. Gee JM, Robertson JF, Ellis IO, et al. Immunocytochemical localization of BCL-2 protein in human breast cancers and its relationship to a series of prognostic markers and response to endocrine therapy. Int J Cancer. 1994;59:619-628.
28. Daidone MG, Luisi A, Veneroni S, Benini E, Silvestrini R. Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Endocr Relat Cancer. 1999;6:61-68.
29. Silvestrini R, Veneroni S, Daidone MG, et al. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst. 1994;86:499-504.
30. Kapranos N, Karaiosifidi H, Valavanis C, Kouri E, Vasilaros S. Prognostic significance of apoptosis related proteins Bcl-2 and Bax in node-negative breast cancer patients. Anticancer Res. 1997;17:2499-2505.
31. van Slooten HJ, Clahsen PC, van Dierendonck JH, et al. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer. 1996;74:78-85.
32. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long-term survival in breast cancer. Am J Pathol. 1994;145:1191-1198.
33. Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol. 1995;177:49-55.
34. Ioachim EE, Malamou-Mitsi V, Kamina SA, Goussia AC, Agnantis NJ. Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, CerbB-2, EGFR and proliferation indices. Anticancer Res. 2000;20:4221-4225.
35. Strasser A. Dr. Josef Steiner Cancer Research Prize Lecture: the role of physiological cell death in neoplastic transformation and in anti-cancer therapy. Int J Cancer. 1999;81:505-511.
36. Cherbonnel-Lasserre C, Gauny S, Kronenberg A. Suppression of apoptosis by Bcl-2 or Bcl-xL promotes susceptibility to mutagenesis. Oncogene. 1996;13:1489-1497.
37. Sierra A, Castellsague X, Escobedo A, et al. Bcl-2 with loss of apoptosis allows accumulation of genetic alterations: a pathway to metastatic progression in human breast cancer. Int J Cancer. 2000;89:142-147.
38. Del Bufalo D, Biroccio A, Leonetti C, Zupi G. Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J. 1997;11:947-953.